Condition
Venom Allergy
Total Trials
5
Recruiting
3
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 4 (2)
Trial Status
Recruiting3
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06935890Phase 4Recruiting
Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation
NCT06876506Recruiting
Identification of B Regulatory Cells by Flow Cytometry
NCT07596303Completed
BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)
NCT07328178Recruiting
Analysis of the Role of IgE Proteoforms in Health and Disease
NCT00684476Phase 4CompletedPrimary
Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings
Showing all 5 trials